Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET

Company Participants

Helen Rubinstein - Director of Investor Relations

Barry Greene - Chief Executive Officer

Jim Doherty - Chief Development Officer

Chris Benecchi - Chief Business Officer

Kimi Iguchi - Chief Financial Officer

Laura Gault - Chief Medical Officer

Conference Call Participants

Tazeen Ahmad - Bank of America

Salveen Richter - Goldman Sachs

Anupam Rama - JPMorgan

Ritu Baral - Cowen

Eason Lee - Needham

Jay Olson - Oppenheimer

Laura Chico - Wedbush Securities

Sumant Kulkarni - Canaccord Genuity

Yatin Suneja - Guggenheim

Tim Lugo - William Blair

Neena Bitritto-Garg - Citi

Douglas Tsao - H.C. Wainwright

Rudy Li - SVB Securities

Gary Nachman - BMO Capital Markets

Brian Abrahams - RBC Capital Markets

Alex Nackenoff - Raymond James

Joon Lee - Truist Securities

Operator

Good morning. Welcome to the Sage Therapeutics' Fourth Quarter and Full-Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction, or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Helen Rubinstein, Director of Investor Relations at Sage.

Helen Rubinstein

Good morning and thank you for joining Sage Therapeutics' fourth quarter and full-year 2022 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com, where you can find the press release related to today's call, as well as the slides that we would be reviewing today.

I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details. We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the fourth quarter and full-year 2022.

We will also be joined by Jim Doherty [Technical Difficulty], who will provide an update on our launch preparations for the zuranolone in MDD and PPD if approved, and we will then be joined Kimi Iguchi, our Chief Financial Officer, who will review the financial results from the fourth quarter and full-year 2022; Laura Gault, our Chief Medical Officer will be available for questions during the Q&A portion of the call.